JP2017529386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529386A5 JP2017529386A5 JP2017526762A JP2017526762A JP2017529386A5 JP 2017529386 A5 JP2017529386 A5 JP 2017529386A5 JP 2017526762 A JP2017526762 A JP 2017526762A JP 2017526762 A JP2017526762 A JP 2017526762A JP 2017529386 A5 JP2017529386 A5 JP 2017529386A5
- Authority
- JP
- Japan
- Prior art keywords
- pro
- arg
- nap
- trp
- hca
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000000539 amino acid group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000002253 acid Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 230000006536 aerobic glycolysis Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- -1 1,2-dihydronaphthyl group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- MJIDYLIDXWGFRN-QMMMGPOBSA-N (2s)-2-[2-(diaminomethylidene)hydrazinyl]-3-phenylpropanoic acid Chemical compound NC(=N)NN[C@H](C(O)=O)CC1=CC=CC=C1 MJIDYLIDXWGFRN-QMMMGPOBSA-N 0.000 claims 1
- NNWQLZWAZSJGLY-VKHMYHEASA-N (2s)-2-azaniumyl-4-azidobutanoate Chemical compound OC(=O)[C@@H](N)CCN=[N+]=[N-] NNWQLZWAZSJGLY-VKHMYHEASA-N 0.000 claims 1
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims 1
- JASNXOXPNZWQRV-UHFFFAOYSA-N 3-azaniumyl-3-naphthalen-2-ylpropanoate Chemical compound C1=CC=CC2=CC(C(CC(O)=O)N)=CC=C21 JASNXOXPNZWQRV-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical group NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 1
- VBOQYPQEPHKASR-VKHMYHEASA-N L-homocysteic acid Chemical compound OC(=O)[C@@H](N)CCS(O)(=O)=O VBOQYPQEPHKASR-VKHMYHEASA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108091026813 Poly(ADPribose) Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- NQIHMZLGCZNZBN-PXNSSMCTSA-N Trp-Trp Chemical group C1=CC=C2C(C[C@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)N)C(O)=O)=CNC2=C1 NQIHMZLGCZNZBN-PXNSSMCTSA-N 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims 1
- 108010068380 arginylarginine Proteins 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 108010045269 tryptophyltryptophan Proteins 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 0 CCC(C)(C)N1[C@](CCCC(CCS(O)(=O)=O)C(CC*N(CCC2)[C@@]2C(N[C@@](CCS(O)(=O)=O)C(N(CCC2)[C@]2C(OC(C)(C)CC)=[U])=C)=C)=[U])CCC1 Chemical compound CCC(C)(C)N1[C@](CCCC(CCS(O)(=O)=O)C(CC*N(CCC2)[C@@]2C(N[C@@](CCS(O)(=O)=O)C(N(CCC2)[C@]2C(OC(C)(C)CC)=[U])=C)=C)=[U])CCC1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1413942.2 | 2014-08-06 | ||
| GB1413942.2A GB2530479A (en) | 2014-08-06 | 2014-08-06 | Peptides useful for treating cancer |
| PCT/EP2015/068056 WO2016020437A1 (en) | 2014-08-06 | 2015-08-05 | Peptides useful for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017529386A JP2017529386A (ja) | 2017-10-05 |
| JP2017529386A5 true JP2017529386A5 (OSRAM) | 2018-09-20 |
Family
ID=51587828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526762A Pending JP2017529386A (ja) | 2014-08-06 | 2015-08-05 | 癌治療に有用なペプチド |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20170313746A1 (OSRAM) |
| EP (1) | EP3177716A1 (OSRAM) |
| JP (1) | JP2017529386A (OSRAM) |
| CN (1) | CN107406485A (OSRAM) |
| AU (1) | AU2015299032A1 (OSRAM) |
| CA (1) | CA2960070A1 (OSRAM) |
| GB (1) | GB2530479A (OSRAM) |
| RU (1) | RU2017106945A (OSRAM) |
| WO (1) | WO2016020437A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391259B (es) | 2015-10-14 | 2025-03-21 | X Therma Inc | Composiciones y métodos para reducir la formación de cristales de hielo. |
| GB201602409D0 (en) * | 2016-02-10 | 2016-03-23 | Warenius Hilmar M | Compositions and uses thereof |
| GB2582571B (en) | 2019-03-25 | 2024-02-28 | Syntherix Ltd | Peptides and use thereof |
| CN114948920B (zh) * | 2021-04-21 | 2024-11-15 | 苏州大学 | 小分子化合物在制备抗肿瘤药物中的应用 |
| GB2628421A (en) | 2023-03-24 | 2024-09-25 | Syntherix Ltd | Peptides and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1349555A4 (en) * | 2000-12-04 | 2007-04-25 | Sloan Kettering Inst Cancer | TREATMENT OF CANCER BY REDUCING INTRACELLULAR ENERGY AND USING PYRIMIDINES |
| WO2003004600A2 (en) * | 2001-07-05 | 2003-01-16 | Yale University | Improvement of viral uptake into cells and tissues |
| US7439031B2 (en) * | 2003-12-15 | 2008-10-21 | The Trustees Of The University Of Pennsylvania | Method of identifying compounds that induce cell death by necrosis |
| GB0804496D0 (en) * | 2008-03-11 | 2008-04-16 | Theryte Ltd | Treating cancer |
| WO2014004935A2 (en) * | 2012-06-27 | 2014-01-03 | Siscapa Assay Technologies, Inc. | Multipurpose mass spectrometric assay panels for peptides |
| JP6306596B2 (ja) * | 2012-10-04 | 2018-04-04 | リサーチ ディベロップメント ファウンデーション | セリンプロテアーゼ分子および療法 |
| WO2014053879A1 (en) * | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
-
2014
- 2014-08-06 GB GB1413942.2A patent/GB2530479A/en not_active Withdrawn
-
2015
- 2015-08-05 JP JP2017526762A patent/JP2017529386A/ja active Pending
- 2015-08-05 AU AU2015299032A patent/AU2015299032A1/en not_active Abandoned
- 2015-08-05 RU RU2017106945A patent/RU2017106945A/ru not_active Application Discontinuation
- 2015-08-05 US US15/501,748 patent/US20170313746A1/en not_active Abandoned
- 2015-08-05 WO PCT/EP2015/068056 patent/WO2016020437A1/en not_active Ceased
- 2015-08-05 CN CN201580054152.2A patent/CN107406485A/zh active Pending
- 2015-08-05 EP EP15745496.8A patent/EP3177716A1/en not_active Withdrawn
- 2015-08-05 CA CA2960070A patent/CA2960070A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| EA202092320A1 (ru) | Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли | |
| CY1122611T1 (el) | Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης | |
| JP2017529386A5 (OSRAM) | ||
| CY1119714T1 (el) | Ενωσεις αναστολεων | |
| CY1121125T1 (el) | Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης | |
| JP2018507197A5 (OSRAM) | ||
| IL260127B (en) | mek inhibitors and methods of using them | |
| TW200744636A (en) | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | |
| MX2010003868A (es) | Cis-imidazolinas quirales. | |
| CY1116929T1 (el) | Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β | |
| CY1111065T1 (el) | Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| CY1114140T1 (el) | Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| MX2016002795A (es) | Compuestos de triazolona y usos de los mismos. | |
| JP2019519512A5 (OSRAM) | ||
| JP2019506392A5 (OSRAM) | ||
| EP4316504A3 (en) | Compounds | |
| JOP20190086A1 (ar) | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب | |
| PH12019500858A1 (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| RU2015150994A (ru) | Новые производные морфолинилантрациклина | |
| JP2016517871A5 (OSRAM) | ||
| NO20030420D0 (no) | Medikament for immunoterapi av maligne tumorer | |
| EP1482933A4 (en) | SIMPLIFIED AND EFFICIENT DERIVATIVES OF IMMUNOSUPPRESSANT AGENTS |